AskNadia: Levemir Insulin Versus Lantus

Dear Nadia, I would like to know, if I normally use Levemir pen insulin, and I run out before my health insurance kicks in, can I use Lantus insulin until I can get coverage for my Levemir ? Rita U Dear Rita: Levemir and Lantus are similar insulins.  Our advisory board member Jane Jeffrie Seley, DNP MSN MPH RN GNP BC-ADM CDE CDTC suggests that

Read more

AskNadia: Accidentally Injected 50 Units of NovoLog Insulin Instead of Lantus

Dear Nadia: I was going to watch a little TV before going to sleep I was wanting to wait up on my husband to get home from work. I grabbed my Lantus and took it in to the bedroom so I wouldn’t forget to take it before falling asleep. After getting all comfy in bed I thought I should just go ahead and take my

Read more

Promising Results Reported for New Insulin

A new kind of long-acting insulin, developed by pharmaceutical giant Sanofi, has shown promising results in clinical trials, according to information released by the company. The investigational insulin, called U300, is based on the glargine molecule, which is also used in Sanofi’s Lantus brand. But U300 works for a longer time than Lantus, reduces blood sugar more consistently (the research term for this is that

Read more

New Type 2 Drugs Change Treatment Decisions

Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation. DPP-4 inhibitors, such as Januvia and Onglyza, now account for 21 percent of treatments. Long-acting insulins,

Read more

Lantus and Levemir: What’s the Difference?

Lantus and Levemir have a lot in common. Both are basal insulin formulas, which means that they last for a long time in the body and act as background insulin, with a slow feed that mimics the constant low output of insulin produced by a healthy pancreas. Both are insulin analogues, which means that their insulin molecules are analogous to human insulin, but engineered, or

Read more

An Interview With Robert Cuddihy, MD, of Sanofi US

Endocrinologist Robert Cuddihy, MD, joined Sanofi US over a year ago to be the company’s Vice President and Medical Diabetes Head in the United States. He is responsible for developing and executing the US strategy for Sanofi’s Diabetes Division, including pharmaceuticals, devices, and other technologies. He previously served as the medical director for several organizations, including the International Diabetes Center-Park Nicollet in Minnesota. Diabetes Health recently

Read more